Monday, October 20, 2025 10/20/2025

Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery

Award Number: R43CA302403
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/02/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery - ABSTRACT There is a need in the market for a true platform technology that processes large volumes of tissues. Syntr Health Technologies has dedicated the last seven years developing the technology that can streamline tissue processing. Our FDA-cleared SyntrFuge System and SyntrFPU360, is a platform technology that can process a variety of different tissue types such as cancer tumor tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, and microsizing adipose tissue for breast cancer reconstructive surgery, of which the global breast cancer reconstruction market size was $2.68 billion in 2021 and growing at a CAGR of 7.1%. Also, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers and knee osteoarthritis. Syntr successfully completed an SBIR Phase I grant where we utilized micronized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that clinically translated successfully into humans. Preliminary human clinical data shows complete diabetic foot ulcer wound closure within 3-5 weeks using autologous adipose tissue processed in the SyntrFuge System. Our platform technology for the rapid processing and/or microsizing of tissues can disrupt these markets in a major way. The seamless large volume processing of tissues using this technology in this Phase I SBIR is paramount to increase favorability in the adoption of this much needed technology in various medical fields.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $356,500 )
2025	2025	SYNTR HEALTH TECHNOLOGIES, INC.	5270 CALIFORNIA AVE STE 300	IRVINE	CA	92617	ORANGE	USA	Cancer Treatment Research	000	1	8/29/2025	NEW	$356,500
														Subtotal = $356,500

Grand Total All Awards = $356,500

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery

Award Number: R43CA302403

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/02/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer